The Claim
In adults with type 2 diabetes and chronic kidney disease who are already receiving ACE inhibitor or ARB therapy, weekly subcutaneous administration of semaglutide at a dose of 1.0 mg reduces the risk of a composite outcome consisting of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 18% compared to placebo.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For adults with type 2 diabetes and kidney problems, taking a weekly semaglutide shot (like Ozempic) cuts their risk of heart attack, stroke, or dying from heart issues by 18% compared to a dummy shot.
See the scientific wording
In adults with type 2 diabetes and chronic kidney disease on ACE inhibitor or ARB therapy, weekly subcutaneous semaglutide at 1.0 mg reduces the risk of a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke by 18% compared to placebo.
What the research says
1 studyStudy: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The study tested the same diabetes medicine (semaglutide) in similar patients and found it reduced heart problems by 18%, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.